



7-13-05

B

15r 1621  
#

CASE 4-30096B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 483 66 907 445  
Express Mail Label Number

July 12, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1621

ZIMMERMANN ET AL.

Examiner: O'Sullivan, Peter G.

APPLICATION NO: 09/991,184

FILED: NOVEMBER 16, 2001

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE  
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS  
USE

**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R.  
§1.97(d).

In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention  
to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/463,097 filed January  
18, 2000, and copies are available therein. However, applicant is willing to send copies of  
any or all of these references at the Examiner's request.

A petition pursuant to 37 C.F.R. §1.97(d) is enclosed herewith.

07/14/2005 SSITHIB1 00000133 190134 09991184

01 FC:1806 180.00 DA

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee required by 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(d).


An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge the above-mentioned \$180 fee and any additional fees which may be required to Deposit Account No. 19-0134 in the name of Novartis.

Statement under 37 C.F.R. §1.97(e)(2)

I, the undersigned, hereby certify that no item of information in this Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than 3 months prior to the filing of this Information Disclosure Statement.

Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852

  
Oona A. Jackson  
Attorney for Applicant  
Reg. No. 48,152

Date:

7/12/05



CASE 4-30096B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV4836690744S  
Express Mail Label Number

July 12, 2005  
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1621

ZIMMERMANN ET AL.

Examiner: O'Sullivan, Peter G.

APPLICATION NO: 09/991,184

FILED: NOVEMBER 16, 2001

FOR: CRYSTAL MODIFICATION OF A N-PHENYL-2-PYRIMIDINEAMINE  
DERIVATIVE, PROCESSES FOR ITS MANUFACTURE AND ITS  
USE

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

PETITION PURSUANT TO 37 CFR §1.97(d)


Sir:

Consideration of the Information Disclosure Statement submitted concurrently herewith is requested. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 for payment of the fee for filing this petition.

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.


Respectfully submitted,

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7852  
Date: 7/12/05

  
Oona A. Jackson  
Attorney for Applicant  
Reg. No. 48,152

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
4-30096B  
APPLICATION NO.  
09/991,184  
APPLICANT  
ZIMMERMANN et al.  
FILING DATE  
NOVEMBER 16, 2001Group  
1621

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Buchdunger et al, "Inhibition of the Abl Protein-Tyrosine Kinase <i>in Vitro</i> and <i>in Vivo</i> by a 2-Phenylaminopyrimidine Derivative," Cancer Research 56, pp. 100-104 (1996)
AS	
AT	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.